Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Can Alzheimer disease be a form of type 3 diabetes?

Accardi G, Caruso C, Colonna-Romano G, Camarda C, Monastero R, Candore G.

Rejuvenation Res. 2012 Apr;15(2):217-21. doi: 10.1089/rej.2011.1289.

PMID:
22533436
2.

SHIP2: a "new" insulin pathway target for aging research.

Accardi G, Virruso C, Balistreri CR, Emanuele F, Licastro F, Monastero R, Porcellini E, Vasto S, Verga S, Caruso C, Candore G.

Rejuvenation Res. 2014 Apr;17(2):221-5. doi: 10.1089/rej.2013.1541.

PMID:
24313349
3.

Polymorphisms in type II SH2 domain-containing inositol 5-phosphatase (INPPL1, SHIP2) are associated with physiological abnormalities of the metabolic syndrome.

Kaisaki PJ, Delépine M, Woon PY, Sebag-Montefiore L, Wilder SP, Menzel S, Vionnet N, Marion E, Riveline JP, Charpentier G, Schurmans S, Levy JC, Lathrop M, Farrall M, Gauguier D.

Diabetes. 2004 Jul;53(7):1900-4.

4.

Metabolic basis of sporadic Alzeimer's disease. role of hormones related to energy metabolism.

Folch J, Pedrós I, Patraca I, Martínez N, Sureda F, Camins A.

Curr Pharm Des. 2013;19(38):6739-48. Review.

PMID:
23530509
5.

Genetic association analysis of inositol polyphosphate phosphatase-like 1 (INPPL1, SHIP2) variants with essential hypertension.

Marçano AC, Burke B, Gungadoo J, Wallace C, Kaisaki PJ, Woon PY, Farrall M, Clayton D, Brown M, Dominiczak A, Connell JM, Webster J, Lathrop M, Caulfield M, Samani N, Gauguier D, Munroe PB.

J Med Genet. 2007 Sep;44(9):603-5. Epub 2007 Jun 8.

6.

INPPL1 is associated with the metabolic syndrome in men with Type 1 diabetes, but not with diabetic nephropathy.

Hyvönen ME, Ihalmo P, Forsblom C, Thorn L, Sandholm N, Lehtonen S, Groop PH.

Diabet Med. 2012 Dec;29(12):1589-95. doi: 10.1111/j.1464-5491.2012.03668.x.

PMID:
22486725
7.

The inositol phosphatase SHIP2 negatively regulates insulin/IGF-I actions implicated in neuroprotection and memory function in mouse brain.

Soeda Y, Tsuneki H, Muranaka H, Mori N, Hosoh S, Ichihara Y, Kagawa S, Wang X, Toyooka N, Takamura Y, Uwano T, Nishijo H, Wada T, Sasaoka T.

Mol Endocrinol. 2010 Oct;24(10):1965-77. doi: 10.1210/me.2010-0163. Epub 2010 Sep 9.

PMID:
20829391
8.

Absence of the lipid phosphatase SHIP2 confers resistance to dietary obesity.

Sleeman MW, Wortley KE, Lai KM, Gowen LC, Kintner J, Kline WO, Garcia K, Stitt TN, Yancopoulos GD, Wiegand SJ, Glass DJ.

Nat Med. 2005 Feb;11(2):199-205. Epub 2005 Jan 16. Erratum in: Nat Med. 2005 Mar;11(3):353.

PMID:
15654325
9.

The role of the inositol polyphosphate 5-phosphatases in cellular function and human disease.

Ooms LM, Horan KA, Rahman P, Seaton G, Gurung R, Kethesparan DS, Mitchell CA.

Biochem J. 2009 Apr 1;419(1):29-49. doi: 10.1042/BJ20081673. Review.

PMID:
19272022
10.

Antisense oligonucleotides against the lipid phosphatase SHIP2 improve muscle insulin sensitivity in a dietary rat model of the metabolic syndrome.

Buettner R, Ottinger I, Gerhardt-Salbert C, Wrede CE, Schölmerich J, Bollheimer LC.

Am J Physiol Endocrinol Metab. 2007 Jun;292(6):E1871-8. Epub 2007 Feb 27.

11.

Single nucleotide polymorphisms on SHIP2 is associated with Type 2 diabetes mellitus in Chinese Han population.

Hao YM, Liu QJ, Wang RY, Cao YP, Zhang Y, Zuo LF.

Eur Rev Med Pharmacol Sci. 2015 Jan;19(1):129-37.

12.

Association of SH-2 containing inositol 5'-phosphatase 2 gene polymorphisms and hyperglycemia.

Ishida S, Funakoshi A, Miyasaka K, Shimokata H, Ando F, Takiguchi S.

Pancreas. 2006 Jul;33(1):63-7.

PMID:
16804414
14.

Impact of transgenic overexpression of SH2-containing inositol 5'-phosphatase 2 on glucose metabolism and insulin signaling in mice.

Kagawa S, Soeda Y, Ishihara H, Oya T, Sasahara M, Yaguchi S, Oshita R, Wada T, Tsuneki H, Sasaoka T.

Endocrinology. 2008 Feb;149(2):642-50. Epub 2007 Nov 26.

PMID:
18039790
15.

The SH2 domain containing inositol polyphosphate 5-phosphatase-2: SHIP2.

Dyson JM, Kong AM, Wiradjaja F, Astle MV, Gurung R, Mitchell CA.

Int J Biochem Cell Biol. 2005 Nov;37(11):2260-5. Review.

PMID:
15964236
16.

SHIP2, a factor associated with diet-induced obesity and insulin sensitivity, attenuates FGF signaling in vivo.

Jurynec MJ, Grunwald DJ.

Dis Model Mech. 2010 Nov-Dec;3(11-12):733-42. doi: 10.1242/dmm.000703. Epub 2010 Jul 8.

17.

Impact of SRC homology 2-containing inositol 5'-phosphatase 2 gene polymorphisms detected in a Japanese population on insulin signaling.

Kagawa S, Sasaoka T, Yaguchi S, Ishihara H, Tsuneki H, Murakami S, Fukui K, Wada T, Kobayashi S, Kimura I, Kobayashi M.

J Clin Endocrinol Metab. 2005 May;90(5):2911-9. Epub 2005 Feb 1.

PMID:
15687335
18.

Discovery and functional characterization of a novel small molecule inhibitor of the intracellular phosphatase, SHIP2.

Suwa A, Yamamoto T, Sawada A, Minoura K, Hosogai N, Tahara A, Kurama T, Shimokawa T, Aramori I.

Br J Pharmacol. 2009 Oct;158(3):879-87. doi: 10.1111/j.1476-5381.2009.00358.x. Epub 2009 Aug 19.

19.

The association between the SH2-containing inositol polyphosphate 5-Phosphatase 2 (SHIP2) and the adaptor protein APS has an impact on biochemical properties of both partners.

Onnockx S, De Schutter J, Blockmans M, Xie J, Jacobs C, Vanderwinden JM, Erneux C, Pirson I.

J Cell Physiol. 2008 Jan;214(1):260-72.

PMID:
17620296
20.

Transcriptional profiling of C2C12 myotubes in response to SHIP2 depletion and insulin stimulation.

Huard C, Martinez RV, Ross C, Johnson JW, Zhong W, Hill AA, Kim R, Paulsen JE, Shih HH.

Genomics. 2007 Feb;89(2):270-9. Epub 2006 Nov 21.

Supplemental Content

Support Center